NCI Director Named as Acting FDA Commissioner

News
Article

Ned Sharpless is tapped to take on acting commissioner role following Gottlieb’s resignation.

One week following the surprise resignation of FDA Commissioner Scott Gottlieb, Norman E. (Ned) Sharpless, head of the National Cancer Institute (NCI), was named acting commissioner of FDA, according to media reports.

The announcement was confirmed by Health and Human Services Secretary Alex Azar at a congressional hearing on March 12, 2019.

Sharpless has served as the director of NCI since October 2017. He previously was director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, served on the faculty at Harvard Medical School, and the University of North Carolina School of Medicine in the Departments of Medicine and Genetics.

He cofounded clinical-stage biotechnology companies G1 Therapeutics and HealthSpan Diagnostics, according to his NCI biography.

Source: NCI

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes